{"pmid":32497298,"title":"Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence.","text":["Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence.","Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID-19), gastrointestinal manifestations are increasingly described. However, data regarding COVID-19-associated pancreatic injury are still limited, as well as the mechanisms underlying COVID-19 induced-pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID-19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS-CoV-2, inflammatory cascade, dehydration and multiple organ dysfunction. This article is protected by copyright. All rights reserved.","J Med Virol","Bruno, Giuseppe","Fabrizio, Claudia","Santoro, Carmen Rita","Buccoliero, Giovanni Battista","32497298"],"abstract":["Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID-19), gastrointestinal manifestations are increasingly described. However, data regarding COVID-19-associated pancreatic injury are still limited, as well as the mechanisms underlying COVID-19 induced-pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID-19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS-CoV-2, inflammatory cascade, dehydration and multiple organ dysfunction. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Bruno, Giuseppe","Fabrizio, Claudia","Santoro, Carmen Rita","Buccoliero, Giovanni Battista"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497298","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26134","keywords":["covid-19","increased lipase","pancreatic injury"],"topics":["Mechanism"],"weight":1,"_version_":1668712823917641728,"score":9.490897,"similar":[{"pmid":32498972,"pmcid":"PMC7254005","title":"SARS-CoV2 RNA detection in a pancreatic pseudocyst sample.","text":["SARS-CoV2 RNA detection in a pancreatic pseudocyst sample.","The involvement of gastrointestinal system in SARS-CoV2 related disease, COVID-19, is increasingly recognized. COVID-19 associated pancreatic injury has been suggested, but its correlation with pancreatic disease is still unclear. In this case report, we describe the detection of SARS-CoV2 RNA in a pancreatic pseudocyst fluid sample collected from a patient with SARS-CoV2 associated pneumonia and a pancreatic pseudocyst developed as a complication of an acute edematous pancreatitis. The detection of SARS-CoV2 within the pancreatic collection arise the question of whether this virus has a tropism for pancreatic tissue and whether it plays a role in pancreatic diseases occurrence.","Pancreatology","Schepis, T","Larghi, A","Papa, A","Miele, L","Panzuto, F","De Biase, L","Annibale, B","Cattani, P","Rapaccini, G L","32498972"],"abstract":["The involvement of gastrointestinal system in SARS-CoV2 related disease, COVID-19, is increasingly recognized. COVID-19 associated pancreatic injury has been suggested, but its correlation with pancreatic disease is still unclear. In this case report, we describe the detection of SARS-CoV2 RNA in a pancreatic pseudocyst fluid sample collected from a patient with SARS-CoV2 associated pneumonia and a pancreatic pseudocyst developed as a complication of an acute edematous pancreatitis. The detection of SARS-CoV2 within the pancreatic collection arise the question of whether this virus has a tropism for pancreatic tissue and whether it plays a role in pancreatic diseases occurrence."],"journal":"Pancreatology","authors":["Schepis, T","Larghi, A","Papa, A","Miele, L","Panzuto, F","De Biase, L","Annibale, B","Cattani, P","Rapaccini, G L"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498972","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.pan.2020.05.016","keywords":["covid-19","endoscopic drainage","pancreatic pseudocyst","sars-cov2"],"topics":["Diagnosis"],"weight":1,"_version_":1668890966359015424,"score":275.69135},{"pmid":32377176,"pmcid":"PMC7201379","title":"Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?","text":["Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?","Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from chemotherapy in order to protect our patients from COVID-19 as much as possible.","JOP","Patel, Rajvi","Saif, Wasif","32377176"],"abstract":["Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from chemotherapy in order to protect our patients from COVID-19 as much as possible."],"journal":"JOP","authors":["Patel, Rajvi","Saif, Wasif"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32377176","source":"PubMed","week":"202019|May 04 - May 10","keywords":["adjuvant chemotherapy","covid-19, pandemics","lymphopenia","neutropenia","pancreatic cancer"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666262687572557825,"score":190.7492},{"pmid":32423899,"title":"ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.","text":["ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.","The COVID-19 pandemic is challenging the capacities of health systems in many countries. National healthcare services have to manage unexpected shortages of healthcare resources that have to be re-allocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers, and save as many lives as possible. Also, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose a guidance to the management of pancreatic cancer during the pandemic, prioritised according to a three-tiered framework, and based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, the authors have separated the prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale is outlined and discussed. The implementation of healthcare services using telemedicine is explored; it reveals itself as functional and effective for limiting patients' need to travel to centres and thereby has the potential to reduce diffusion of SARS-CoV-2. Pancreatic cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems.","ESMO Open","Catanese, Silvia","Pentheroudakis, George","Douillard, Jean-Yves","Lordick, Florian","32423899"],"abstract":["The COVID-19 pandemic is challenging the capacities of health systems in many countries. National healthcare services have to manage unexpected shortages of healthcare resources that have to be re-allocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers, and save as many lives as possible. Also, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose a guidance to the management of pancreatic cancer during the pandemic, prioritised according to a three-tiered framework, and based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, the authors have separated the prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale is outlined and discussed. The implementation of healthcare services using telemedicine is explored; it reveals itself as functional and effective for limiting patients' need to travel to centres and thereby has the potential to reduce diffusion of SARS-CoV-2. Pancreatic cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems."],"journal":"ESMO Open","authors":["Catanese, Silvia","Pentheroudakis, George","Douillard, Jean-Yves","Lordick, Florian"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423899","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/esmoopen-2020-000804","keywords":["covid-19 pandemic"],"topics":["Prevention"],"weight":1,"_version_":1667252837840584704,"score":160.24812},{"pmid":32278764,"pmcid":"PMC7144611","title":"COVID-19 and diabetes: Knowledge in progress.","text":["COVID-19 and diabetes: Knowledge in progress.","AIMS: We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management. METHODS: We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: \"SARS-CoV-2\", \"COVID-19\", \"infection\", \"pathogenesis\", \"incubation period\", \"transmission\", \"clinical features\", \"diagnosis\", \"treatment\", \"diabetes\", with interposition of the Boolean operator \"AND\". RESULTS: The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug interactions might reduce adverse outcomes. CONCLUSIONS: Suggestions are made on the possible pathophysiological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted.","Diabetes Res Clin Pract","Hussain, Akhtar","Bhowmik, Bishwajit","do Vale Moreira, Nayla Cristina","32278764"],"abstract":["AIMS: We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management. METHODS: We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: \"SARS-CoV-2\", \"COVID-19\", \"infection\", \"pathogenesis\", \"incubation period\", \"transmission\", \"clinical features\", \"diagnosis\", \"treatment\", \"diabetes\", with interposition of the Boolean operator \"AND\". RESULTS: The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug interactions might reduce adverse outcomes. CONCLUSIONS: Suggestions are made on the possible pathophysiological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted."],"journal":"Diabetes Res Clin Pract","authors":["Hussain, Akhtar","Bhowmik, Bishwajit","do Vale Moreira, Nayla Cristina"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278764","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.diabres.2020.108142","keywords":["covid-19","clinical management","diabetes","pathogenesis","sars-cov-2"],"locations":["Boolean"],"e_drugs":["Glucose","Chloroquine","Thiazolidinediones"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491562491904,"score":156.56052},{"pmid":32107909,"title":"[Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease].","text":["[Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease].","Objective: To explorethe proper protective measures for pancreaticdiseases treatment during theoutbreak of 2019 coronavirus disease(COVID-19). Method: Clinical data of four cases of patients that suffered COVID-19from February 2(nd), 2020 to February 9(th), 2020 in pancreatic surgery were reviewed.After the first patientscuffednosocomial infection of COVID-19, the general protective measures in our department wereupdated.Only one patient was admitted to each room alone, with no more than one caregiver.The body temperature of care givers was measuredtwice a day.Primary protections were applied to all staff.The floor was sterilized using disinfectant with an effective chlorine concentration of 1000 mg/L.The protective measures for interventional procedures were as follow.Primary protection was applied to the operators ofcentral venipuncture catheter, percutaneous abdominal/pleural drainage, percutaneous retroperitoneal drainage, percutaneous transhepatic cholangial drainage and other surgical procedures with local anesthesiaand epidural anesthesia.Secondary protection was applied to the operators of endoscopic retrograde cholangiopancreatography and surgical procedures with general anesthesia. Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators. Conclusions: The caregivers of patients are potential infection source of COVID-19.Enhanced protective measures including the management measures of caregivers can decrease the risk of nosocomial infection of COVID-19.","Zhonghua Wai Ke Za Zhi","Gou, S M","Yin, T","Xiong, J X","Peng, T","Li, Y","Wu, H S","32107909"],"abstract":["Objective: To explorethe proper protective measures for pancreaticdiseases treatment during theoutbreak of 2019 coronavirus disease(COVID-19). Method: Clinical data of four cases of patients that suffered COVID-19from February 2(nd), 2020 to February 9(th), 2020 in pancreatic surgery were reviewed.After the first patientscuffednosocomial infection of COVID-19, the general protective measures in our department wereupdated.Only one patient was admitted to each room alone, with no more than one caregiver.The body temperature of care givers was measuredtwice a day.Primary protections were applied to all staff.The floor was sterilized using disinfectant with an effective chlorine concentration of 1000 mg/L.The protective measures for interventional procedures were as follow.Primary protection was applied to the operators ofcentral venipuncture catheter, percutaneous abdominal/pleural drainage, percutaneous retroperitoneal drainage, percutaneous transhepatic cholangial drainage and other surgical procedures with local anesthesiaand epidural anesthesia.Secondary protection was applied to the operators of endoscopic retrograde cholangiopancreatography and surgical procedures with general anesthesia. Results: During Feb 2(nd), 2020 to Feb 9(th), 2020, four patients in our department were diagnosed with COVID-19, of which one was died of COVID-19, two were cured, and one is still in hospital for COVID-19.After the update ofprotective measures in our department, no more nosocomial infection of COVID-19occurred.Two central venipuncture catheter, three percutaneous abdominal/pleural drainage, one percutaneous retroperitoneal drainage, one percuteneous transhepatic cholecyst drainage and one open surgery with general anesthesia were performed with no infection of operators. Conclusions: The caregivers of patients are potential infection source of COVID-19.Enhanced protective measures including the management measures of caregivers can decrease the risk of nosocomial infection of COVID-19."],"journal":"Zhonghua Wai Ke Za Zhi","authors":["Gou, S M","Yin, T","Xiong, J X","Peng, T","Li, Y","Wu, H S"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32107909","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112139-20200224-00123","keywords":["2019 coronavirus disease","coronavirus infections","nosocomial infection","novel coronavirus pneumonia","pancreatic disease","prevention of infection"],"e_drugs":["Chlorine"],"topics":["Prevention"],"weight":1,"_version_":1666138492871114752,"score":146.48262}]}